Dana-Farber Cancer Institute

https://www.dana-farber.org/

 

Dana-Farber Cancer Institute
R

ESMO 2023 Insights: "AIM-HN Study - Evaluating Tipifarnib in mHRAS, Recurrent or Metastatic HNSCC"

By Dana-Farber Cancer Institute FEATURING Robert Haddad
By Dana-Farber Cancer Institute FEATURING Robert Haddad
65 views
November 6, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
Head and Neck
02:34
Dana-Farber Cancer Institute

ESMO 2023 Insights: "AIM-HN Study - Evaluating Tipifarnib in mH…

Feat. R. Haddad